Action - SNTA

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,343

Prix Achat

0,31

Prix Vente

0,34

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

0,343

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeutics PR Newswire NEW...

Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals

Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ: SNTA) announced today that the annual meeting of stockholders to approve, among other things...

Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June

Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by...

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics PR Newswire NEW YORK, May 27, 2016 NEW YORK, May...

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

– Combined Company Well-Funded to Generate Data from Multiple Phase 2 Studies – – Paul A. Friedman, M.D. Named Chairman and Chief...

Synta Reports Third Quarter 2015 Financial Results

Announces Reduction in Force, Appointment of Scott Morenstein to Board of Directors Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today...

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Company to Host Conference Call on Wednesday, October 21 at 8:00 AM ET Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the...

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the formation of an Expert Oncology Panel to provide guidance on research and...

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Alan C. Rigby, Ph.D., as the Company’s Senior Vice President...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

SNTA - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 0,343

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JTAIJet AI Inc	US$ 10,1006 (148,78%)	149,38M
EDITEditas Medicine Inc	US$ 3,19 (83,33%)	49,89M
SINTSiNtx Technologies Inc	US$ 4,79 (69,86%)	70,97M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,363 (63,07%)	215,48M
AGHAureus Greenway Holdings Inc	US$ 3,8501 (42,07%)	1,02M
CNSPCNS Pharmaceuticals Inc	US$ 0,0838 (-41,19%)	88,17M
HCTIHealthcare Triangle Inc	US$ 0,4409 (-38,76%)	3,19M
NKLANikola Corporation	US$ 0,4711 (-38,49%)	110,5M
BPTHBio Path Holdings Inc	US$ 0,1322 (-37,05%)	2,14M
GLSTUGlobal Star Acquisition Inc	US$ 7,26 (-36,04%)	4,41k
ADTXAditxt Inc	US$ 0,1288 (17,09%)	612,1M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0616 (13,03%)	482,51M
SMCISuper Micro Computer Inc	US$ 60,25 (7,97%)	338,03M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,363 (63,07%)	215,48M
NVDANVIDIA Corporation	US$ 139,23 (-0,12%)	168,03M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Synta Pharmaceuticals Corp. (MM) (SNTA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SNTA Dernières nouvelles

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...

Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals

Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Synta Reports Third Quarter 2015 Financial Results

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

SNTA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Synta Pharmaceuticals Corp. (MM) (SNTA) Cours

Synta Pharmaceuticals Corp. (MM) (SNTA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SNTA Dernières nouvelles

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...

Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals

Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Synta Reports Third Quarter 2015 Financial Results

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

SNTA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS